Photodynamic Therapy Combined With Bevacizumab vs Bevacizumab Alone for Neovascular Age-related Macular Degeneration

Inclusion Criteria: * All lesion subtype of CNV secondary to age-related macular. * sub-foveal CNV. * patients who fail to respond to Photodynamic therapy. * patients who are not eligible for PDT (Greatest linear dimension of the lesion \>/= 5400 um, CNV with hemorrhage \>/= 50 % of the entire lesion, minimally classic or occult CNV with greatest linear dimension of the lesion \>/= 4600 um.). * Patients affected by Pigment Epithelium Detachment with CNV. * Patients affected by Retinal Angiomatous Proliferation. * Willingness and ability to participate and provide written informed consent. Exclusion Criteria: * Individuals with choroidal neovascularization from causes other than AMD (Myopia, Angioid Streaks). * Any intraocular surgery within 2 months in the study eye. * Prior retinal or vitreous surgery including posterior segment vitrectomy or scleral buckling in the study eye. * Any significant ocular disease that has compromised or could compromise vision in the study eye. * Prior stroke, myocardial infarction, or end-stage malignancy. * Active hepatitis or clinically significant liver disease, renal failure. * Any patient with recent history of new onset cardiac disease or thromboembolic CNS event in the past. * Patients who are in an experimental therapy study or who have received experimental therapy within the last 12 weeks. * Patients who are a poor medical risk because of other systemic diseases or active uncontrolled infections.